

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
21 October 2021 (21.10.2021)



(10) International Publication Number  
**WO 2021/209019 A1**

(51) International Patent Classification:

*C07K 16/28* (2006.01) *A61P 35/00* (2006.01)  
*C12N 15/13* (2006.01) *G01N 33/574* (2006.01)  
*A61K 39/395* (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2021/087616

(22) International Filing Date:

16 April 2021 (16.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

202010304381.8 17 April 2020 (17.04.2020) CN

(71) Applicant: HUTCHISON MEDIPHARMA LIMITED

[CN/CN]; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN).

(72) Inventors: YANG, Yizhen; Building 4, 720 Cailun Road,

Pilot Free Trade Zone, Shanghai 201203 (CN). CAI, Yu; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). LI, Xiong; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). ZHOU, Lei; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). QING, Weiguo; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). SU, Wei-Guo; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN).

(74) Agent: ZHONGZI LAW OFFICE; 7F, New Era Building,

26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-OX40 ANTIBODY AND USES THEREOF

(57) Abstract: The present invention provides an anti-OX40 antibody or antigen-binding fragment thereof, a preparation method therefor and the use for treating OX40-related diseases or conditions.

